08/17/23 7:15 AMNasdaq : CVAC earningsCureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business UpdateInitiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSKInitiated Phase 1 study of cancer vaccine candidate, CVGBM, for surgically resected glioblastoma; recruitment ofRHEA-AIneutral
08/01/23 7:15 AMNasdaq : CVAC clinical trialcovid-19CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSKPhase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidatesVaccine candidates developed in collaboration with GSK within COVID-19 vaccine development programTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 1, 2023 / CureVac N.V.RHEA-AIneutral
07/21/23 9:00 AMNasdaq : CVAC Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow BiotechnologyYarrow Biotechnology, Inc., an RTW Investments, LP- incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system, today announced the appointment of Dr. Igor Splawski as Chief Scientific Officer. Splawski was previously the Chief Scientific Officer and a...RHEA-AIneutral
07/14/23 7:15 AMNasdaq : CVAC CureVac Announces Update to the Management TeamTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 14, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Dr. IgorRHEA-AIneutral
07/13/23 7:15 AMNasdaq : CVAC CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property RightsCases in Germany and the U.S. broadened by asserting additional, new intellectual property rightsThree new intellectual property rights added to infringement lawsuit against Pfizer/BioNTech in Germany, increasing number of asserted intellectual property rights to eightTenth patent added toRHEA-AIneutral
06/20/23 7:25 AMNasdaq : CVAC clinical trialCureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected GlioblastomaCancer vaccine candidate CVGBM utilizes single mRNA, encoding eight epitopes of tumor-associated antigens with demonstrated relevance in glioblastomaStudy designed to evaluate safety and immunogenicity in patients with glioblastoma after surgical resection and radiotherapyFirst study to applyRHEA-AIneutral
06/20/23 7:10 AMNasdaq : CVAC managementCureVac Appoints International Financial Expert Michael Brosnan to Supervisory BoardTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 20, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment ofRHEA-AIneutral
06/19/23 1:33 PMNasdaq : CVAC CureVac Announces Voting Results of General MeetingTÜBINGEN, GERMANY and BOSTON, USA / ACCESSWIRE / June 19, 2023 / CureVac N.V. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of theRHEA-AIneutral
05/30/23 7:30 AMNasdaq : CVAC earningsCureVac Announces Financial Results for the First Quarter of 2023 and Provides Business UpdateInitiated Phase 1/2 study in seasonal flu with multivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSKFiled infringement counterclaim in U.S. patent litigation with Pfizer/BioNTech; case filed under nine CureVac patents;RHEA-AIneutral
05/19/23 7:15 AMNasdaq : CVAC CureVac Announces Developments in Patent Litigation with Pfizer/BioNTechMotion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timelineCureVac is filing counterclaim in U.S. court under nine patents covering foundational mRNA innovations highly relevant to the design,RHEA-AIneutral